SG11202105730TA - Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof - Google Patents

Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof

Info

Publication number
SG11202105730TA
SG11202105730TA SG11202105730TA SG11202105730TA SG11202105730TA SG 11202105730T A SG11202105730T A SG 11202105730TA SG 11202105730T A SG11202105730T A SG 11202105730TA SG 11202105730T A SG11202105730T A SG 11202105730TA SG 11202105730T A SG11202105730T A SG 11202105730TA
Authority
SG
Singapore
Prior art keywords
benzamides
pyrazolyl
amino
compositions
methods
Prior art date
Application number
SG11202105730TA
Inventor
Zhaokui Wan
Michael Lawrence Vazquez
Xiaodong Li
Original Assignee
Lynk Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynk Pharmaceuticals Co Ltd filed Critical Lynk Pharmaceuticals Co Ltd
Publication of SG11202105730TA publication Critical patent/SG11202105730TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
SG11202105730TA 2018-12-14 2019-12-16 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof SG11202105730TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2018/121165 WO2020118683A1 (en) 2018-12-14 2018-12-14 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
PCT/CN2019/125552 WO2020119819A1 (en) 2018-12-14 2019-12-16 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof

Publications (1)

Publication Number Publication Date
SG11202105730TA true SG11202105730TA (en) 2021-06-29

Family

ID=71076270

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105730TA SG11202105730TA (en) 2018-12-14 2019-12-16 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof

Country Status (14)

Country Link
US (5) US20230002362A1 (en)
EP (1) EP3877381A4 (en)
JP (1) JP7459094B2 (en)
KR (1) KR20210125983A (en)
CN (1) CN113227074A (en)
AU (3) AU2019399939A1 (en)
BR (1) BR112021011147A2 (en)
CA (3) CA3230060A1 (en)
EA (1) EA202191188A1 (en)
IL (1) IL283968A (en)
MX (1) MX2021006866A (en)
SG (1) SG11202105730TA (en)
TW (1) TW202039474A (en)
WO (2) WO2020118683A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627775A (en) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 Small molecule compound
TW202204333A (en) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin inhibitors and methods of use for treating cancer
CN112661655B (en) * 2020-12-29 2022-02-18 江苏云朴医药新材料科技有限公司 1-aminomethyl-1-cyclopropanol compound and synthetic method thereof
WO2024041397A1 (en) * 2022-08-22 2024-02-29 Hangzhou Highlightll Pharmaceutical Co., Ltd Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
WO2023151724A1 (en) * 2023-05-19 2023-08-17 凌科药业(杭州)有限公司 Crystal form of pyrazolyl-amino-pyrimidinyl derivative, and preparation method therefor and use thereof
CN116983312A (en) * 2023-05-24 2023-11-03 凌科药业(杭州)有限公司 Pharmaceutical composition, external preparation, and preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2704599C (en) * 2007-11-16 2015-05-12 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
KR20140047092A (en) * 2011-07-28 2014-04-21 셀좀 리미티드 Heterocyclyl pyrimidine analogues as jak inhibitors
DE102011112978A1 (en) * 2011-09-09 2013-03-14 Merck Patent Gmbh benzonitrile derivatives
KR101361149B1 (en) * 2012-07-17 2014-02-24 전남대학교산학협력단 Gene Implicated in Drought Stress Tolerance and Transformed Plants with the Same
MX370103B (en) * 2013-12-11 2019-12-02 Biogen Ma Inc Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology.
CN106349224A (en) * 2016-08-03 2017-01-25 山东大学 JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof
CN108864057B (en) * 2017-05-16 2020-03-31 山东大学 JAK and HDAC double-target-point inhibitor containing 4-aminopyrazole structure and preparation method and application thereof
WO2020206588A1 (en) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110330484B (en) * 2019-07-18 2022-08-26 中国药科大学 Substituted phenyl pyrimidine derivative as JAK kinase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application
CN110627775A (en) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 Small molecule compound

Also Published As

Publication number Publication date
US20240083881A1 (en) 2024-03-14
EP3877381A1 (en) 2021-09-15
TW202039474A (en) 2020-11-01
EA202191188A1 (en) 2021-11-29
CA3230060A1 (en) 2020-06-18
US20230416235A1 (en) 2023-12-28
US20220298144A1 (en) 2022-09-22
IL283968A (en) 2021-07-29
MX2021006866A (en) 2021-11-17
CA3122872A1 (en) 2020-06-18
EP3877381A4 (en) 2022-08-24
AU2019399939A1 (en) 2021-06-24
US20230002362A1 (en) 2023-01-05
BR112021011147A2 (en) 2021-08-31
WO2020119819A1 (en) 2020-06-18
AU2024201128A1 (en) 2024-03-14
JP7459094B2 (en) 2024-04-01
KR20210125983A (en) 2021-10-19
WO2020118683A1 (en) 2020-06-18
JP2022510925A (en) 2022-01-28
AU2024201125A1 (en) 2024-03-14
CA3230071A1 (en) 2020-06-18
US20240025882A1 (en) 2024-01-25
CN113227074A (en) 2021-08-06

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
IL272367A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
IL280963A (en) Anti-gdf15 antibodies, compositions and methods of use
EP3313404A4 (en) Therapeutic compositions, combinations, and methods of use
EP3595653A4 (en) Compositions of plinabulin and use thereof
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
IL283968A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
GB2582100B (en) CAS12C Compositions and methods of use
EP3337823A4 (en) Carrier-binding agent compositions and methods of making and using the same
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL244278A0 (en) Cannabinoid compositions, methods of manufacture and use thereof
EP3691677A4 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
ZA201906169B (en) Synthekine compositions and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL289763A (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
IL276135A (en) Compositions and methods of use
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL287014A (en) Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
IL272834A (en) Amantadine compositions, preparations thereof, and methods of use
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
EP3773654C0 (en) Polypharmaceutical drug compositions and related methods
EP3367998A4 (en) Novel method of use and compositions
IL269884B1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
EP3717004A4 (en) Compositions for interferon blockade and methods of using same